蛋白C、抗凝血酶及凝血因子Ⅷ活性变化与肺癌合并肺栓塞后治疗的关系

doi:10.3969/j.issn.1673-8640.2014.10.003

检验医学 ›› 2014, Vol. 29 ›› Issue (10): 995-999.DOI: 10.3969/j.issn.1673-8640.2014.10.003

蛋白C、抗凝血酶及凝血因子Ⅷ活性变化与肺癌合并肺栓塞后治疗的关系

陈环¹, 张鹏¹, 刘军锋²

1.天津医科大学肿瘤医院检验科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室,天津 300060;
2.天津泰达国际心血管病医院天津医科大学心血管病临床学院检验科,天津 300457

收稿日期:2014-06-04 出版日期:2014-10-30 发布日期:2014-10-22
通讯作者: 张　鹏,联系电话:022-23340123;刘军锋,联系电话:022-65208763。
作者简介:陈　环,女,1978年生,学士,主管技师,主要从事临床检验及肿瘤相关研究工作。

Correlation of the activities of protein C, antithrombin and coagulation factor Ⅷ with the treatment of lung cancer with pulmonary embolism

CHEN Huan¹, ZHANG Peng¹, LIU Junfeng

1. Department of Clinical Laboratory, Cancer Hospital, Tianjin Medical University; National Clinical Rsearch Center of Cancer; Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060,China;
2. TEDA International Cardiovascular Hospital; Department of Clinical Laboratory, Cardiovascular Disease Clinical College, Tianjin Medical University, Tianjin 300457,China

Received:2014-06-04 Online:2014-10-30 Published:2014-10-22

摘要/Abstract

摘要：

目的探讨蛋白C(PC)、抗凝血酶(AT)及凝血因子Ⅷ(FⅧ)活性变化与肺癌合并肺血栓栓塞[简称肺栓塞(PE)]后治疗的关系。方法选择肺癌合并PE患者(肺癌+PE组)98例及肺癌患者(肺癌组)100例。记录两组性别、年龄并检测脂蛋白(a)[Lp(a)]、总胆固醇(TC)、甘油三酯(TG)、C反应蛋白(CRP)、凝血酶时间(TT)、血小板数量(PLT)、纤维蛋白原(Fbg)等指标。检测肺癌+PE组治疗5~7 d及肺癌组入院时的PC、AT、FⅧ、D-二聚体水平。应用Logistic回归分析肺癌合并PE后治疗5~7 d凝血-纤溶状态的影响因素,并采用受试者工作特征(ROC)曲线分析影响因素的诊断效能。结果肺癌+PE组Lp(a)、TC、TG、TT均明显高于肺癌组(P<0.05)。肺癌+PE组PC、AT、FⅧ、D-二聚体水平明显高于肺癌组(P<0.01)。Logistic逐步回归及ROC曲线分析显示,PC、AT、FⅧ是肺癌合并PE后治疗5~7 d凝血-纤溶状态的影响因素,ROC曲线下面积均>0.90。结论肺癌合并PE中期治疗需关注PC、AT、FⅧ对凝血-纤溶系统的影响,其活性水平可用来评估一定时期内的治疗效果和治疗方案。

关键词: 蛋白质C, 抗凝血酶, 凝血因子&, #x02167, 肺癌, 肺血栓栓塞

Abstract:

Objective To investigate the correlation of the activities of protein C(PC), antithrombin(AT) and coagulation factor Ⅷ(FⅧ) with the treatment of lung cancer with pulmonary embolism(PE). Methods A total of 98 patients with lung cancer and PE were enrolled as lung cancer with PE group. A total of 100 patients with lung cancer were enrolled as lung cancer group. Their sex and age were recorded, and lipoprotein(a)[Lp(a)], total cholesterol(TC), triglyceride (TG), C-reactive protein(CRP), thrombin time(TT), platelet (PLT) and fibrinogen(Fbg)in the 2 groups were determined, respectively. PC, AT, FⅧ and D-dimer were determined in lung cancer with PE group after 5-7 d of treatment. Logistic regression analysis was used to analyze the factors influencing coagulation-fibrinolysis after 5-7 d of treatment in lung cancer with PE group. The receiver operating characteristic(ROC) curve was used to analyze the diagnostic efficiency of these factors. Resutls Lp(a), TC, TG and TT in lung cancer with PE group were significantly higher than those in lung cancer group (P<0.05). The levels of PC, AT, FⅧ and D-dimer were significantly higher in lung cancer with PE group than those in lung cancer group (P<0.01).Logistic regression analysis and ROC curve analysis showed that PC, AT and FⅧ were influencing factors of coagulation-fibrinolysis after 5-7 d of treatment in lung cancer with PE group, and the areas under ROC curve were >0.90. Conclusions The influence of PC, AT and FⅧ on coagulation-fibrinolysis should be concerned in midterm treatment of lung cancer with PE, and their activities can be used to assess the therapeutic efficiency and treatment program in a given period.

Key words: Protein C, Antithrombin, Coagulation factor &, #x02167, Lung cancer, Pulmonary embolism

中图分类号:

R446.1

陈环, 张鹏, 刘军锋. 蛋白C、抗凝血酶及凝血因子Ⅷ活性变化与肺癌合并肺栓塞后治疗的关系[J]. 检验医学, 2014, 29(10): 995-999.

CHEN Huan, ZHANG Peng, LIU Junfeng. Correlation of the activities of protein C, antithrombin and coagulation factor Ⅷ with the treatment of lung cancer with pulmonary embolism[J]. , 2014, 29(10): 995-999.

参考文献

[1] 林辛锋,王群,白春学,等. 肺癌合并慢性阻塞性肺疾病诊治概况调查[J]. 中华医学杂志,2011,91(40): 2815-2818.
[2] Cushman M. Epidemiology and risk factors for venous thrombosis[J]. Semin Hematol, 2007,44(2): 62-69.
[3] 中华医学会呼吸学分会. 肺血栓栓塞症的诊断与治疗指南(草案)[J]. 中华结核和呼吸杂志,2001,24(5):259-264.
[4] 王峻,周卫华,许林,等. 肺癌合并肺栓塞危险因素及预后的临床分析[J]. 中国肺癌杂志,2011,14(10):780-784.
[5] Pollack CV,Schreiber D,Goldhaber SZ,et al. Clinical characteristics,management,and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry)[J]. J Am Coll Cardiol,2011,57(6):700-706.
[6] 叶絮,刘晓力,冯莹,等. 蛋白C基因复合杂合突变导致的肺栓塞及家系研究[J]. 南方医科大学学报,2012,32(1):109-112.
[7] Somajo S,Koshiar RL,Norström E,et al. Protein S and factor V in regulation of coagulation on platelet microparticles by activated protein C[J]. Thromb Res, 2014, 134(1): 144-152.
[8] 付乃宽,陈永利,张敬霞,等. 急性肺栓塞患者溶栓治疗后凝血-纤溶指标的变化[J]. 中华血液学杂志,2007,28(3):206-208.
[9] 廖洪利,蒋小丽,田刚. 慢性阻塞性肺疾病急性加重期患者检测AT-Ⅲ的意义[J]. 现代检验医学杂志,2012,27(5):133-134.
[10] Wang YQ,Chen QL,Zhu D,et al. Portal vein thrombosis after aortic valve replacement surgery in a patient with antithrombin Ⅲ deficiency -case presentation[J]. J Cardiothorac Surg,2014,9(1):73.
[11] 王晓,朱均权.凝血因子Ⅴ、Ⅷ和组织因子与2型糖尿病合并冠心病的关系[J].检验医学,2014,29(1):34-37.
[12] 潘以锋,张皓. 静脉血栓栓塞症与凝血因子Ⅷ关系研究进展[J]. 中华实验外科杂志,2009,26(11):1579-1580.
[13] Payne AB,Miller CH,Hooper WC,et al. High factor Ⅷ, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites[J]. Ethn Dis,2014,24(2):169-174.

[1]	周韵斓, 沈立松. 液体活检标志物在非小细胞肺癌中的临床应用和挑战[J]. 检验医学, 2023, 38(9): 807-811.
[2]	陈颖, 李伟, 林涛, 杨丽. PFTK1表达与非小细胞肺癌微血管密度和患者预后的关系[J]. 检验医学, 2023, 38(7): 634-639.
[3]	杨忠信, 李晓宇, 陈涛, 曹文军. IL-8和MMP-2在非小细胞肺癌患者胸腔镜肺段切除术预后评估中的价值[J]. 检验医学, 2023, 38(4): 342-346.
[4]	宋世伟, 李景武, 林韬, 刘泽宇, 王志强, 孙卫东. GPNMB与非小细胞肺癌患者肿瘤免疫浸润和预后的相关性[J]. 检验医学, 2023, 38(4): 347-351.
[5]	柳行强, 宁立芬, 李琳, 陈忠成. FR⁺-CTC、ANXA2、ProGRP与肺癌临床病理特征的相关性[J]. 检验医学, 2022, 37(8): 735-740.
[6]	陈文欣, 薛赢俊, 李贞, 杨洁, 邵华卿, 胡晓波. 胃癌、结直肠癌患者凝血和纤溶标志物水平变化[J]. 检验医学, 2022, 37(5): 496-498.
[7]	赵明娜, 张宸梓, 洪秋双, 娄加陶. IL-8/miR-182正反馈调控轴在非小细胞肺癌中的作用机制研究[J]. 检验医学, 2022, 37(4): 349-355.
[8]	王建英, 王珊珊, 朱俊, 黄晓春, 万玉香, 刘云. 肺癌患者化疗后肺部感染病原菌分布及耐药性分析[J]. 检验医学, 2022, 37(4): 356-359.
[9]	徐润灏, 邹琛, 曹芸, 陈风, 刘怡菁, 张舒林, 张洁. 早期非小细胞肺癌患者血清氨基酸检测的临床意义[J]. 检验医学, 2022, 37(12): 1157-1163.
[10]	满宪凤, 贺小停, 张莹, 俞卫卫, 王齐, 尹汉维, 王润洁. 硫氧还蛋白还原酶在肺癌疗效监测中的应用[J]. 检验医学, 2022, 37(1): 56-59.
[11]	徐润灏, 邹琛, 张洁, 李敏, 张舒林. 胆汁酸谱在肺炎和肺癌鉴别诊断中的应用价值[J]. 检验医学, 2021, 36(1): 1-7.
[12]	彭焦武, 孙承谋. miR-124a和miR-449a对非小细胞肺癌的诊断价值[J]. 检验医学, 2021, 36(1): 34-38.
[13]	王子谨, 张晓膺. 载脂蛋白M在非小细胞肺癌A549细胞增殖、迁移和侵袭中的作用[J]. 检验医学, 2020, 35(9): 937-942.
[14]	刘勤, 陈冲, 岳超. 提高D-二聚体的临界值对评估肺癌患者预后的价值[J]. 检验医学, 2020, 35(8): 763-766.
[15]	袁世洋, 刘川, 欧阳晓春, 谢军平, 贺荣芝, 李里香, 邹叶青. 3D数字PCR检测NSCLC患者血浆EGFR T790M基因突变的临床意义[J]. 检验医学, 2020, 35(8): 806-810.

蛋白C、抗凝血酶及凝血因子Ⅷ活性变化与肺癌合并肺栓塞后治疗的关系

Correlation of the activities of protein C, antithrombin and coagulation factor Ⅷ with the treatment of lung cancer with pulmonary embolism

RichHTML

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics